Literature DB >> 25382802

The wingless-related integration site-5a/secreted frizzled-related protein-5 system is dysregulated in human sepsis.

D M Schulte1, D Kragelund, N Müller, I Hagen, G Elke, A Titz, D Schädler, J Schumacher, N Weiler, B Bewig, S Schreiber, M Laudes.   

Abstract

Sepsis and type 2 diabetes exhibit insulin resistance as a common phenotype. In type 2 diabetes we and others have recently provided evidence that alterations of the proinflammatory wingless-related integration site (wnt)-5a/anti-inflammatory secreted frizzled-related protein (sFRP)-5 system are involved in the pathogenesis of insulin resistance. The aim of the present study was to investigate whether this novel cytokine system is dysregulated in human sepsis, which may indicate a potential mechanism linking inflammation to metabolism. In this single-centre prospective observational study, critically ill adult septic patients were examined and proinflammatory wnt5a and wnt5a inhibitor sFRP5 were measured in serum samples by enzyme-linked immunosorbent assay (ELISA) at admission to the intensive care unit (ICU) and 5 days later. Sixty sepsis patients were included, and 30 healthy individuals served as controls. Wnt5a levels were found to be increased significantly in septic patients compared to healthy controls (2·21 ± 0·33 versus 0·32 ± 0·03 ng/ml, P < 0·0001). In contrast, sFRP5 was not altered significantly in septic patients (19·72 ± 3·06 versus 17·48 ± 6·38 ng/ml, P = 0·07). On admission to the ICU, wnt5a levels exhibited a significant positive correlation with the leucocyte count (rs  = 0·3797, P = 0·004). Interestingly, in patients recovering from sepsis, wnt5a levels declined significantly within 5 days (2·17 ± 0·38-1·03 ± 0·28 ng/ml, P < 0·01). In contrast, if sepsis was worsening, wnt5a levels increased in the same time-period by trend (2·34 ± 0·59-3·25 ± 1·02 ng/ml, P > 0·05). sFRP5 levels did not change significantly throughout the study period. The wnt5a/sFRP5 system is altered in human sepsis and might therefore be of interest for future studies on molecular pathophysiology of this common human disease.
© 2014 British Society for Immunology.

Entities:  

Keywords:  cytokines; human; inflammation

Mesh:

Substances:

Year:  2015        PMID: 25382802      PMCID: PMC4367097          DOI: 10.1111/cei.12484

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Trial failure prompts soul-searching for critical-care specialists.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

2.  After Xigris, researchers look to new targets to combat sepsis.

Authors:  Sarah C P Williams
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

Review 3.  Emerging drugs for the treatment of sepsis.

Authors:  Antigone Kotsaki; Evangelos J Giamarellos-Bourboulis
Journal:  Expert Opin Emerg Drugs       Date:  2012-07-11       Impact factor: 4.191

4.  Secreted frizzled-related protein 5 suppresses adipocyte mitochondrial metabolism through WNT inhibition.

Authors:  Hiroyuki Mori; Tyler C Prestwich; Michael A Reid; Kenneth A Longo; Isabelle Gerin; William P Cawthorn; Vedrana S Susulic; Venkatesh Krishnan; Andy Greenfield; Ormond A Macdougald
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

5.  Adipose tissue macrophages inhibit adipogenesis of mesenchymal precursor cells via wnt-5a in humans.

Authors:  R Bilkovski; D M Schulte; F Oberhauser; J Mauer; B Hampel; C Gutschow; W Krone; M Laudes
Journal:  Int J Obes (Lond)       Date:  2011-02-01       Impact factor: 5.095

6.  Turning off the inflammatory, but not the metabolic, flames.

Authors:  Ediz S Calay; Gökhan S Hotamisligil
Journal:  Nat Med       Date:  2013-03       Impact factor: 53.440

7.  [Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI)].

Authors:  K Reinhart; F M Brunkhorst; H-G Bone; J Bardutzky; C-E Dempfle; H Forst; P Gastmeier; H Gerlach; M Gründling; S John; W Kern; G Kreymann; W Krüger; P Kujath; G Marggraf; J Martin; K Mayer; A Meier-Hellmann; M Oppert; C Putensen; M Quintel; M Ragaller; R Rossaint; H Seifert; C Spies; F Stüber; N Weiler; A Weimann; K Werdan; T Welte
Journal:  Anaesthesist       Date:  2010-04       Impact factor: 1.041

Review 8.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

9.  Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10.

Authors:  Claudia Pereira; Dominik J Schaer; Esther B Bachli; Michael O Kurrer; Gabriele Schoedon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-03       Impact factor: 8.311

Review 10.  Origin and physiological roles of inflammation.

Authors:  Ruslan Medzhitov
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

View more
  14 in total

1.  WNT ligands contribute to the immune response during septic shock and amplify endotoxemia-driven inflammation in mice.

Authors:  Marcela Gatica-Andrades; Dimitrios Vagenas; Jessica Kling; Tam T K Nguyen; Helen Benham; Ranjeny Thomas; Heinrich Körner; Bala Venkatesh; Jeremy Cohen; Antje Blumenthal
Journal:  Blood Adv       Date:  2017-07-10

2.  Wnt5A/Ryk signaling critically affects barrier function in human vascular endothelial cells.

Authors:  Tom Skaria; Esther Bachli; Gabriele Schoedon
Journal:  Cell Adh Migr       Date:  2016-05-09       Impact factor: 3.405

3.  Wnt5a/FZD5/CaMKII signaling pathway mediates the effect of BML-111 on inflammatory reactions in sepsis.

Authors:  Muhu Chen; Wu Zhong; Yingchun Hu; Jitao Liu; Xianfu Cai
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  miR-23a-3p inhibits sepsis-induced kidney epithelial cell injury by suppressing Wnt/β-catenin signaling by targeting wnt5a.

Authors:  Junwei Ye; Huibing Feng; Zhiyong Peng
Journal:  Braz J Med Biol Res       Date:  2022-02-28       Impact factor: 2.590

5.  WIF1 prevents Wnt5A mediated LIMK/CFL phosphorylation and adherens junction disruption in human vascular endothelial cells.

Authors:  Tom Skaria; Esther Bachli; Gabriele Schoedon
Journal:  J Inflamm (Lond)       Date:  2017-05-19       Impact factor: 4.981

Review 6.  The Wnt antagonist and secreted frizzled-related protein 5: implications on lipid metabolism, inflammation, and type 2 diabetes mellitus.

Authors:  Ling-Bin Liu; Xiao-Dong Chen; Xiang-Yu Zhou; Qing Zhu
Journal:  Biosci Rep       Date:  2018-07-02       Impact factor: 3.840

7.  Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling.

Authors:  Charlotte M Flynn; Yvonne Garbers; Juliane Lokau; Daniela Wesch; Dominik M Schulte; Matthias Laudes; Wolfgang Lieb; Samadhi Aparicio-Siegmund; Christoph Garbers
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

Review 8.  Sfrp5/Wnt Pathway: A Protective Regulatory System in Atherosclerotic Cardiovascular Disease.

Authors:  Shan Tong; Qingwei Ji; Yu Du; Xiaogang Zhu; Caizhong Zhu; Yujie Zhou
Journal:  J Interferon Cytokine Res       Date:  2019-06-13       Impact factor: 2.607

9.  Wnt-Signaling Inhibitor Wnt-C59 Suppresses the Cytokine Upregulation in Multiple Organs of Lipopolysaccharide-Induced Endotoxemic Mice via Reducing the Interaction between β-Catenin and NF-κB.

Authors:  Jaewoong Jang; Jaewon Song; Inae Sim; Young V Kwon; Yoosik Yoon
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

10.  Umbilical Cord SFRP5 Levels of Term Newborns in Relation to Normal and Excessive Gestational Weight Gain.

Authors:  Żaneta Kimber-Trojnar; Jolanta Patro-Małysza; Marcin Trojnar; Dorota Darmochwał-Kolarz; Jan Oleszczuk; Bożena Leszczyńska-Gorzelak
Journal:  Int J Mol Sci       Date:  2019-01-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.